Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX: RAC
Price
Latest News
Race Oncology 2019 Annual General Meeting Presentation
Overview of Race Oncology's new "5 path" strategy for the development of Bisantrene.
Race appoints Dr Daniel Tillett Chief Scientific Officer
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific
Prof Borje Andersson to Chair RAC Clinical Advisory Board
Race Oncology is pleased to announce that Professor Borje Andersson has agreed to chair Race’s
Race reveals new strategy for cancer drug Bisantrene
Race Oncology has revealed its new “5 Path” clinical development strategy for its cancer drug,
Don't miss important updates
Get the latest news & announcement and stay up-to-date.